gms | German Medical Science

122. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

05. bis 08.04.2005, München

Malignant pleural mesothelioma – new intrapleural adjuvant strategies during pleuropneumonectomy – in vitro study

Meeting Abstract

  • corresponding author I. Opitz - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • S. Hillinger - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • M. Curti - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • S. Donaldson - Klinik für Onkologie, Universitätsklinik Zürich, Schweiz
  • D. Lardinois - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz
  • R. Stahel - Klinik für Onkologie, Universitätsklinik Zürich, Schweiz
  • W. Weder - Klinik für Thoraxchirurgie, Universitätsklinik Zürich, Schweiz

Deutsche Gesellschaft für Chirurgie. 122. Kongress der Deutschen Gesellschaft für Chirurgie. München, 05.-08.04.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc05dgch3056

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgch2005/05dgch363.shtml

Veröffentlicht: 15. Juni 2005

© 2005 Opitz et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Introduction

The poor prognosis of malignant pleural mesothelioma with a median survival of 9 months for untreated patients is due to a locally aggressive growht pattern. Even with multimodal treatment strategies including extrapleural pneumonectomy combined with chemotherapy and radiotherapy, local recurrence is common. Intrapleural adjuvant therapy regimes are an attractive treatment option for local tumor control. The adjuvant use of intrapleural taurolidin, a synthetic broad-spectrum antibiotic with antiproliferative activity on gastrointestinal tumors and povidone-iodine was evaluated in an in-vitro pilot study.

Materials

Two human mesothelioma cell lines (ZL5 and ZL55) cultivated from tumor biopsy after pleuropneumonectomy and pleural effusion of malignant mesothelioma patients as well as a rat malignant mesothelioma cell (II-45) established from experimentally induced meostheliolmas in Fisher 344 rats exposed to asbestos. Cell growth was measured by use of colorimetric assay, based on the reduction of the tetrazolium salt MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), by mitochondrial dehydrogenases, in viable cells. Taurolidine 2% was added in a volume of 50 ml to achieve a final concentration ranging from 0.1-100 mM. Povidone-iodine was added in a concentration of 0.1, 1, 2.5, 5, 7.5 and 10 %. Control wells received 50 ml of medium. At different time points, MTT assay was performed. Substrate cleavage was monitored at 570 nm by a Synergy HT (Biotek, Vermont, USA) microplate reader and analyzed using the KO4 software 3.4 Microplate Data Analysis. Each sample was performed in triplicate. The IC50 was calculated as the concentration required to inhibit cell growth by 50%. The mean IC50 + SD for each cell line was calculated from 3 independent experiments.

Results

Taurolidine 2 % and povidone iodine showed inlfuence on cell growth of the humancell line (epithelial and mixed type). A similar effect could be observed for the rat cell line.

Discussion

The cytotoxic influence of Povidone iodine and Taurolidine 2% may be an adjuvant therapy option during pleuropneumonectomy for malignant pleural mesothelioma. In vivo studies are planned in order to further investigate the influence.